Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new tracer match the gold standard for heart scans?

NCT ID NCT07761728

Diagnosis Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This trial is testing whether a new PET imaging tracer, 18F-flurpiridaz, can detect coronary artery disease as accurately as the current standard, 82Rb-chloride. The study will involve 60 adults scheduled for a clinically indicated PET scan. Researchers will compare the diagnostic performance of the two tracers using coronary CT angiography as a reference standard, potentially offering a new option for heart imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-flurpiridaz, a radioactive tracer used in PET imaging
What this could lead to
If 18F-flurpiridaz proves as effective as the standard tracer, it could offer a more accessible or convenient option for diagnosing coronary artery disease.
What could go wrong
This is a relatively small study, and results may not apply to all patients. The new tracer might not match the standard's accuracy, and there are always risks associated with radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for a clinically indicated 82Rb-Chloride PET MPI at the West Los Angeles Veterans Affairs Medical Center / Greater Los Angeles Veterans Affairs Healthcare System.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient scheduled for a clinically indicated 82Rb-chloride PET MPI * Age ≥ 18 years * Ability to provide consent Exclusion Criteria: * Previous participation in a 18F-flurpiridaz clinical trial * Prior myocardial infarction * Prior coronary revascularization (percutaneous coronary intervention and/or coronary artery bypass grafting) * History of orthotopic heart transplantation * Inability to control heart rate \< 65 bpm * Frequent ventricular or atrial ectopy leading to irregular cardiac rhythm * Creatinine ≥ 1.4 mg/dL * Pregnant or breast-feeding status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary microvascular disorder Microvascular Angina

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Coronary microvascular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West Los Angeles Veterans Affairs Medical Center

    Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.